The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-VEGF Drug Market Research Report 2025
Synopsis
Global Anti-VEGF Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-VEGF Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Anti-VEGF Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
F. Hoffmann-La Roche Ltd
Amgen Inc
Pfizer, Inc
Xbrane Biopharma AB
Allergan
Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc
Segment by Type
Avastin
Lucentis
Eylea
Segment by Application
Age-related Macular Degeneration
Macular Edema Following Retinal Vein Occlusion
Diabetic Macular Edema
Diabetic Retinopathy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Anti-VEGF Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Global Anti-VEGF Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-VEGF Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Anti-VEGF Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
F. Hoffmann-La Roche Ltd
Amgen Inc
Pfizer, Inc
Xbrane Biopharma AB
Allergan
Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc
Segment by Type
Avastin
Lucentis
Eylea
Segment by Application
Age-related Macular Degeneration
Macular Edema Following Retinal Vein Occlusion
Diabetic Macular Edema
Diabetic Retinopathy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Anti-VEGF Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Anti-VEGF Drug Market Overview
1.1 Product Overview and Scope of Anti-VEGF Drug
1.2 Anti-VEGF Drug Segment by Type
1.2.1 Global Anti-VEGF Drug Market Value Comparison by Type (2023-2029)
1.2.2 Avastin
1.2.3 Lucentis
1.2.4 Eylea
1.3 Anti-VEGF Drug Segment by Application
1.3.1 Global Anti-VEGF Drug Market Value by Application: (2023-2029)
1.3.2 Age-related Macular Degeneration
1.3.3 Macular Edema Following Retinal Vein Occlusion
1.3.4 Diabetic Macular Edema
1.3.5 Diabetic Retinopathy
1.4 Global Anti-VEGF Drug Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Drug Revenue 2018-2029
1.4.2 Global Anti-VEGF Drug Sales 2018-2029
1.4.3 Global Anti-VEGF Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Anti-VEGF Drug Market Competition by Manufacturers
2.1 Global Anti-VEGF Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Anti-VEGF Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Anti-VEGF Drug Average Price by Manufacturers (2018-2023)
2.4 Global Anti-VEGF Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Anti-VEGF Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Drug, Product Type & Application
2.7 Anti-VEGF Drug Market Competitive Situation and Trends
2.7.1 Anti-VEGF Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-VEGF Drug Players Market Share by Revenue
2.7.3 Global Anti-VEGF Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-VEGF Drug Retrospective Market Scenario by Region
3.1 Global Anti-VEGF Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Anti-VEGF Drug Global Anti-VEGF Drug Sales by Region: 2018-2029
3.2.1 Global Anti-VEGF Drug Sales by Region: 2018-2023
3.2.2 Global Anti-VEGF Drug Sales by Region: 2024-2029
3.3 Global Anti-VEGF Drug Global Anti-VEGF Drug Revenue by Region: 2018-2029
3.3.1 Global Anti-VEGF Drug Revenue by Region: 2018-2023
3.3.2 Global Anti-VEGF Drug Revenue by Region: 2024-2029
3.4 North America Anti-VEGF Drug Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Anti-VEGF Drug Sales by Country (2018-2029)
3.4.3 North America Anti-VEGF Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Drug Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Anti-VEGF Drug Sales by Country (2018-2029)
3.5.3 Europe Anti-VEGF Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Anti-VEGF Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Anti-VEGF Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGF Drug Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Anti-VEGF Drug Sales by Country (2018-2029)
3.7.3 Latin America Anti-VEGF Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-VEGF Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Anti-VEGF Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Anti-VEGF Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Drug Sales by Type (2018-2029)
4.1.1 Global Anti-VEGF Drug Sales by Type (2018-2023)
4.1.2 Global Anti-VEGF Drug Sales by Type (2024-2029)
4.1.3 Global Anti-VEGF Drug Sales Market Share by Type (2018-2029)
4.2 Global Anti-VEGF Drug Revenue by Type (2018-2029)
4.2.1 Global Anti-VEGF Drug Revenue by Type (2018-2023)
4.2.2 Global Anti-VEGF Drug Revenue by Type (2024-2029)
4.2.3 Global Anti-VEGF Drug Revenue Market Share by Type (2018-2029)
4.3 Global Anti-VEGF Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Anti-VEGF Drug Sales by Application (2018-2029)
5.1.1 Global Anti-VEGF Drug Sales by Application (2018-2023)
5.1.2 Global Anti-VEGF Drug Sales by Application (2024-2029)
5.1.3 Global Anti-VEGF Drug Sales Market Share by Application (2018-2029)
5.2 Global Anti-VEGF Drug Revenue by Application (2018-2029)
5.2.1 Global Anti-VEGF Drug Revenue by Application (2018-2023)
5.2.2 Global Anti-VEGF Drug Revenue by Application (2024-2029)
5.2.3 Global Anti-VEGF Drug Revenue Market Share by Application (2018-2029)
5.3 Global Anti-VEGF Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche Ltd
6.1.1 F. Hoffmann-La Roche Ltd Corporation Information
6.1.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.1.3 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product Portfolio
6.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.2 Amgen Inc
6.2.1 Amgen Inc Corporation Information
6.2.2 Amgen Inc Description and Business Overview
6.2.3 Amgen Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Amgen Inc Anti-VEGF Drug Product Portfolio
6.2.5 Amgen Inc Recent Developments/Updates
6.3 Pfizer, Inc
6.3.1 Pfizer, Inc Corporation Information
6.3.2 Pfizer, Inc Description and Business Overview
6.3.3 Pfizer, Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer, Inc Anti-VEGF Drug Product Portfolio
6.3.5 Pfizer, Inc Recent Developments/Updates
6.4 Xbrane Biopharma AB
6.4.1 Xbrane Biopharma AB Corporation Information
6.4.2 Xbrane Biopharma AB Description and Business Overview
6.4.3 Xbrane Biopharma AB Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Xbrane Biopharma AB Anti-VEGF Drug Product Portfolio
6.4.5 Xbrane Biopharma AB Recent Developments/Updates
6.5 Allergan
6.5.1 Allergan Corporation Information
6.5.2 Allergan Description and Business Overview
6.5.3 Allergan Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Allergan Anti-VEGF Drug Product Portfolio
6.5.5 Allergan Recent Developments/Updates
6.6 Bayer AG
6.6.1 Bayer AG Corporation Information
6.6.2 Bayer AG Description and Business Overview
6.6.3 Bayer AG Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bayer AG Anti-VEGF Drug Product Portfolio
6.6.5 Bayer AG Recent Developments/Updates
6.7 Regeneron Pharmaceuticals Inc.
6.6.1 Regeneron Pharmaceuticals Inc. Corporation Information
6.6.2 Regeneron Pharmaceuticals Inc. Description and Business Overview
6.6.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product Portfolio
6.7.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
6.8 Viatris Inc
6.8.1 Viatris Inc Corporation Information
6.8.2 Viatris Inc Description and Business Overview
6.8.3 Viatris Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Viatris Inc Anti-VEGF Drug Product Portfolio
6.8.5 Viatris Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Drug Industry Chain Analysis
7.2 Anti-VEGF Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Drug Production Mode & Process
7.4 Anti-VEGF Drug Sales and Marketing
7.4.1 Anti-VEGF Drug Sales Channels
7.4.2 Anti-VEGF Drug Distributors
7.5 Anti-VEGF Drug Customers
8 Anti-VEGF Drug Market Dynamics
8.1 Anti-VEGF Drug Industry Trends
8.2 Anti-VEGF Drug Market Drivers
8.3 Anti-VEGF Drug Market Challenges
8.4 Anti-VEGF Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
